Updated

Research found that tirzepatide, sold as Mounjaro and Zepbound, activated calorie-burning brown fat in obese mice, suggesting the popular GLP-1 drug's metabolic benefits may extend beyond appetite suppression. If confirmed in humans, the discovery could help explain the drug's outsized weight-loss effects and inspire broader obesity and diabetes treatments. The findings add to intense scientific interest in understanding the full mechanisms behind GLP-1 drugs' effectiveness.